Detalhe da pesquisa
1.
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
Int J Cancer
; 152(6): 1243-1258, 2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36346290
2.
Emotional processes in partners' quality of life at various stages of breast cancer pathway: a longitudinal study.
Qual Life Res
; 32(4): 1085-1094, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36418525
3.
Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress.
Psychooncology
; 31(5): 848-855, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34989072
4.
Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer.
BMC Cancer
; 21(1): 815, 2021 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34266398
5.
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
Clin Chem
; 66(8): 1093-1101, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32712650
6.
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
Breast Cancer Res
; 21(1): 121, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727113
7.
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Int J Cancer
; 145(12): 3359-3369, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31087564
8.
The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
BMC Cancer
; 19(1): 110, 2019 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30700265
9.
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
Br J Cancer
; 119(1): 76-79, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880907
10.
Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
Breast Cancer Res Treat
; 165(3): 611-621, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28685212
11.
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
PLoS Med
; 13(12): e1002201, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28027327
12.
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.
Breast Cancer Res Treat
; 157(2): 307-318, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27167986
13.
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.
BMC Cancer
; 15: 659, 2015 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26449988
14.
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.
Future Oncol
; 11(16): 2283-97, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26260807
15.
¹8F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Eur J Nucl Med Mol Imaging
; 41(3): 428-37, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24196916
16.
HER2-positive breast cancer: ¹8F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Eur J Nucl Med Mol Imaging
; 41(8): 1525-33, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24647576
17.
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Eur J Nucl Med Mol Imaging
; 41(3): 416-27, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24258007
18.
Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
JAMA Netw Open
; 7(4): e244435, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568692
19.
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
J Immunother Cancer
; 12(1)2024 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38290768
20.
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study.
Cancer Rep (Hoboken)
; 6(1): e1732, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36302744